Go Local And Stay Flexible: Unlocking Market Access For Novel Drugs In China
Executive Summary
Although regulatory improvement in China has raised hopes that more novel drugs will enter the market, a lack of reimbursement and rounds of price negotiations still pose challenges. A recent report sheds lights on some remedies for policy makers and drug makers.
You may also be interested in...
BeiGene Bags $750m, Sees China Reforms Creating New Opportunities
A spectacular secondary offering will enable Beijing-based BeiGene to expand in both novel R&D and manufacturing in 2018, driven largely by an integrated China-global approach, its CFO says.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.